Evidence map›Paper›PMID 24093477›Full record

ArticleRespiratory research2013

Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.

Shannon Cope, James F Donohue, Jeroen P Jansen, Matthias Kraemer, Gorana Capkun-Niggli, Michael Baldwin, Felicity Buckley, Alexandra Ellis, Paul Jones

Open access · goldAbstract readComparative StudyNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 11 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 11 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.International journal of chronic obstructive pulmonary disease · 2015
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Observational
  20. Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.International journal of chronic obstructive pulmonary disease · 2018
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Shannon CopeDivision of Clinical Science, St George's University of London, London SW17 0RE, UK. pjones@sgul.ac.uk.
James F Donohue
Jeroen P Jansen
Matthias Kraemer
Gorana Capkun-Niggli
Michael Baldwin
Felicity Buckley
Alexandra Ellis
Paul Jones
Boston University · USNovartis (Switzerland) · CHNovartis (United Kingdom) · GBPiedmont International University · USSt George's, University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinicians are faced with an increasingly difficult choice regarding the optimal bronchodilator for patients with chronic obstructive pulmonary disease (COPD) given the number of new treatments. The objective of this study is to evaluate the comparative efficacy of indacaterol 75/150/300 μg once daily (OD), glycopyrronium bromide 50 μg OD, tiotropium bromide 18 μg/5 μg OD, salmeterol 50 μg twice daily (BID), formoterol 12 μg BID, and placebo for moderate to severe COPD.

methodsForty randomized controlled trials were combined in a Bayesian network meta-analysis. Outcomes of interest were trough and post-dose forced expiratory volume in 1 second (FEV1), St. George's Respiratory Questionnaire (SGRQ) score and responders (≥4 points), and Transition Dyspnea Index (TDI) score and responders (≥1 point) at 6 months.

resultsIndacaterol was associated with a higher trough FEV1 than other active treatments (difference for indacaterol 150 μg and 300 μg versus placebo: 152 mL (95% credible interval (CrI): 126, 179); 160 mL (95% CrI: 133, 187)) and the greatest improvement in SGRQ score (difference for indacaterol 150 μg and 300 μg versus placebo: -3.9 (95% CrI -5.2, -2.6); -3.6 (95% CrI -4.8, -2.3)). Glycopyrronium and tiotropium 18 μg resulted in the next best estimates for both outcomes with minor differences (difference for glycopyrronium versus tiotropium for trough FEV1 and SGRQ: 18 mL (95% CrI: -16, 51); -0.55 (95% CrI: -2.04, 0.92).

conclusionIn terms of trough FEV1 and SGRQ score indacaterol, glycopyrronium, and tiotropium are expected to be the most effective bronchodilators.

Indexed as

Bayes TheoremAlbuterolBronchodilator AgentsDelayed-Action PreparationsDose-Response Relationship, DrugEthanolaminesFormoterol FumarateGlycopyrrolateHumansIndansPulmonary Disease, Chronic ObstructiveQuinolonesRandomized Controlled Trials as TopicSalmeterol XinafoateScopolamine DerivativesSeverity of Illness IndexAlbuterolBronchodilator AgentsDelayed-Action PreparationsEthanolaminesFormoterol FumarateGlycopyrrolateindacaterolIndansQuinolonesSalmeterol XinafoateScopolamine DerivativesTiotropium Bromide

Identifiers

PMID24093477
PMCPMC4014806
OpenAlexW2171280425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.